Key result
Pentoxifylline shows no overall benefit over xanthinol nicotinate in occlusive cerebrovascular disease despite earlier improvement.
Pentoxifylline--3,7-dimethyl-1(5-oxo-hexyl) xanthine--a new vasodilator compound, was tried in 28 cases of occlusive cerebrovascular disease. A similar group of 24 patients were given xanthinol nicotinate. Although in terms of degree of improvement there was no significant difference in the two treatment groups, improvement was earlier in the group treated with pentoxifylline. No significant side effects were observed with any of the two drugs used in the present study.
No takes yet. Share an insight, caveat, or question.
Sen et al. (1977) studied occlusive cerebrovascular disease (n=52). Pentoxifylline vs. Xanthinol nicotinate was evaluated on degree of improvement. Pentoxifylline showed no significant difference in the degree of improvement compared to xanthinol nicotinate for occlusive cerebrovascular disease, though clinical improvement occurred earlier.
Synapse has enriched 5 related papers. Consider them for comparative context: